Levetiracetam
Product manufactured by Taro Pharmaceuticals U.s.a., Inc.
Indications and Purposes
| 1 Indications And Usage Levetiracetam Is Indicated For The Treatment Of Partial-Onset Seizures In Patients 1 Month Of Age And Older ( 1.1 ) Levetiracetam Is Indicated For Adjunctive Therapy For The Treatment Of: Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy ( 1.2 ) Primary Generalized Tonic-Clonic Seizures In Patients 6 Years Of Age And Older With Idiopathic Generalized Epilepsy ( 1.3 ) 1.1 Partial-Onset Seizures Levetiracetam Is Indicated For The Treatment Of Partial-Onset Seizures In Patients 1 Month Of Age And Older. 1.2 Myoclonic Seizures In Patients With Juvenile Myoclonic Epilepsy Levetiracetam Is Indicated As Adjunctive Therapy For The Treatment Of Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures Levetiracetam Is Indicated As Adjunctive Therapy For The Treatment Of Primary Generalized Tonic-Clonic Seizures In Patients 6 Years Of Age And Older With Idiopathic Generalized Epilepsy. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Levetiracetam |
|
ZINC1547851 |